Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy
Objectives. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction. Background. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infar...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 1995-01, Vol.25 (1), p.218-223 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 223 |
|---|---|
| container_issue | 1 |
| container_start_page | 218 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 25 |
| creator | White, Harvey D French, John K Hamer, Andrew W Brown, Michael A Williams, Barbara F Ormiston, John A Cross, David B |
| description | Objectives. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction.
Background. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infarction. The incidence of late reocclusion and the effects of antiplatelet therapy are unknown.
Methods. To investigate the importance of antiplatelet therapy for the prevention of late reocclusion, 215 patients who had a patent infarct-related artery 4 weeks after myocardial infarction were randomized in a double-blind manner to receive either a combination of 25 mg of aspirin and 200 mg of dipyridamole twice daily or placebo. One hundred fifty-four patients underwent further coronary arteriography 1 year later.
Results. At 1 year, 38 (25%) of 154 patients had reocclusion of the infarct-related artery; 18 (23%) of 79 patients receiving aspirin and dipyridamole had late reocclusion versus 20 (27%) of 75 who received placebo (p = NS). The rate of reocclusion was related to the severity of the residual coronary artery stenosis at 4 weeks ( |
| doi_str_mv | 10.1016/0735-1097(94)00331-J |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77086849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>073510979400331J</els_id><sourcerecordid>77086849</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-450543117941942cefbcdf1f85424a8dfad1cf555e99e319b150f861aae4d2c43</originalsourceid><addsrcrecordid>eNp9kMFuEzEQhi0EakPhDajkA6rgsNQT21m7h0qoaoGqUi9wthx7LEw33q3tgPL2eEmUI6eRZr5_NPMR8g7YJ2CwumQ9lx0w3X_Q4iNjnEN3_4IsQErVcan7l2RxRE7J61J-McZWCvQJOel7rSSTC1LuMj5vMVWacXRu2JY4JjoGOtk6d2MKNrvaZRxaw1ObK-aIha6x_kFMVNBWngq1yVOgO7T5it6GgK6WeY1NNU5zdMBK60_Mdtq9Ia-CHQq-PdQz8uPu9vvN1-7h8cu3m88PnRNLVjvRDhQcoNcCtFg6DGvnAwQlxVJY5YP14IKUErVGDnoNkgW1AmtR-KUT_Ixc7PdOeWw_lmo2sTgcBptw3BbT90ytlNANFHvQ5bGUjMFMOW5s3hlgZnZtZpFmFmm0MP9cm_sWOz_s36436I-hg9w2f3-Y2-LsELJNLpYjxrmSmkHDrvcYNhe_I2ZTXMTk0MfcNBo_xv_f8RcuGpu7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77086849</pqid></control><display><type>article</type><title>Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>White, Harvey D ; French, John K ; Hamer, Andrew W ; Brown, Michael A ; Williams, Barbara F ; Ormiston, John A ; Cross, David B</creator><creatorcontrib>White, Harvey D ; French, John K ; Hamer, Andrew W ; Brown, Michael A ; Williams, Barbara F ; Ormiston, John A ; Cross, David B</creatorcontrib><description>Objectives. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction.
Background. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infarction. The incidence of late reocclusion and the effects of antiplatelet therapy are unknown.
Methods. To investigate the importance of antiplatelet therapy for the prevention of late reocclusion, 215 patients who had a patent infarct-related artery 4 weeks after myocardial infarction were randomized in a double-blind manner to receive either a combination of 25 mg of aspirin and 200 mg of dipyridamole twice daily or placebo. One hundred fifty-four patients underwent further coronary arteriography 1 year later.
Results. At 1 year, 38 (25%) of 154 patients had reocclusion of the infarct-related artery; 18 (23%) of 79 patients receiving aspirin and dipyridamole had late reocclusion versus 20 (27%) of 75 who received placebo (p = NS). The rate of reocclusion was related to the severity of the residual coronary artery stenosis at 4 weeks (<50% stenosis 9.2%; 50% to 69% stenosis 11.6%; 70% to 89% stenosis 30.4%; ≥ 90% stenosis 70%, p < 0.01). The majority of reocclusions were silent, and only 17 (45%) of 38 were clinically associated with further infarction. There were no differences for a hierarchic end point of cardiac death, myocardial infarction or revascularization (14.8% aspirin and dipyridamole vs. 17.8% placebo).
Conclusions. Late reocclusion of the patent infarct-related artery is a frequent event, occurring in 25% of patients. Antiplatelet therapy with the combination of aspirin and dipyridamole does not alter the overall rate of late reocclusion. Other strategies are required to reduce late reocclusion.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/0735-1097(94)00331-J</identifier><identifier>PMID: 7798505</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aspirin - administration & dosage ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Coronary Angiography ; Coronary Disease - complications ; Coronary Disease - epidemiology ; Coronary Disease - prevention & control ; Coronary Vessels - drug effects ; Dipyridamole - administration & dosage ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - drug therapy ; Myocardial Infarction - etiology ; Myocardial Infarction - mortality ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - therapeutic use ; Prognosis ; Recurrence ; Risk Factors ; Thrombolytic Therapy ; Time Factors ; Vascular Patency - drug effects</subject><ispartof>Journal of the American College of Cardiology, 1995-01, Vol.25 (1), p.218-223</ispartof><rights>1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-450543117941942cefbcdf1f85424a8dfad1cf555e99e319b150f861aae4d2c43</citedby><cites>FETCH-LOGICAL-c420t-450543117941942cefbcdf1f85424a8dfad1cf555e99e319b150f861aae4d2c43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/073510979400331J$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,4036,4037,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3385901$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7798505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>White, Harvey D</creatorcontrib><creatorcontrib>French, John K</creatorcontrib><creatorcontrib>Hamer, Andrew W</creatorcontrib><creatorcontrib>Brown, Michael A</creatorcontrib><creatorcontrib>Williams, Barbara F</creatorcontrib><creatorcontrib>Ormiston, John A</creatorcontrib><creatorcontrib>Cross, David B</creatorcontrib><title>Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>Objectives. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction.
Background. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infarction. The incidence of late reocclusion and the effects of antiplatelet therapy are unknown.
Methods. To investigate the importance of antiplatelet therapy for the prevention of late reocclusion, 215 patients who had a patent infarct-related artery 4 weeks after myocardial infarction were randomized in a double-blind manner to receive either a combination of 25 mg of aspirin and 200 mg of dipyridamole twice daily or placebo. One hundred fifty-four patients underwent further coronary arteriography 1 year later.
Results. At 1 year, 38 (25%) of 154 patients had reocclusion of the infarct-related artery; 18 (23%) of 79 patients receiving aspirin and dipyridamole had late reocclusion versus 20 (27%) of 75 who received placebo (p = NS). The rate of reocclusion was related to the severity of the residual coronary artery stenosis at 4 weeks (<50% stenosis 9.2%; 50% to 69% stenosis 11.6%; 70% to 89% stenosis 30.4%; ≥ 90% stenosis 70%, p < 0.01). The majority of reocclusions were silent, and only 17 (45%) of 38 were clinically associated with further infarction. There were no differences for a hierarchic end point of cardiac death, myocardial infarction or revascularization (14.8% aspirin and dipyridamole vs. 17.8% placebo).
Conclusions. Late reocclusion of the patent infarct-related artery is a frequent event, occurring in 25% of patients. Antiplatelet therapy with the combination of aspirin and dipyridamole does not alter the overall rate of late reocclusion. Other strategies are required to reduce late reocclusion.</description><subject>Aspirin - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Coronary Angiography</subject><subject>Coronary Disease - complications</subject><subject>Coronary Disease - epidemiology</subject><subject>Coronary Disease - prevention & control</subject><subject>Coronary Vessels - drug effects</subject><subject>Dipyridamole - administration & dosage</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prognosis</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Thrombolytic Therapy</subject><subject>Time Factors</subject><subject>Vascular Patency - drug effects</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFuEzEQhi0EakPhDajkA6rgsNQT21m7h0qoaoGqUi9wthx7LEw33q3tgPL2eEmUI6eRZr5_NPMR8g7YJ2CwumQ9lx0w3X_Q4iNjnEN3_4IsQErVcan7l2RxRE7J61J-McZWCvQJOel7rSSTC1LuMj5vMVWacXRu2JY4JjoGOtk6d2MKNrvaZRxaw1ObK-aIha6x_kFMVNBWngq1yVOgO7T5it6GgK6WeY1NNU5zdMBK60_Mdtq9Ia-CHQq-PdQz8uPu9vvN1-7h8cu3m88PnRNLVjvRDhQcoNcCtFg6DGvnAwQlxVJY5YP14IKUErVGDnoNkgW1AmtR-KUT_Ixc7PdOeWw_lmo2sTgcBptw3BbT90ytlNANFHvQ5bGUjMFMOW5s3hlgZnZtZpFmFmm0MP9cm_sWOz_s36436I-hg9w2f3-Y2-LsELJNLpYjxrmSmkHDrvcYNhe_I2ZTXMTk0MfcNBo_xv_f8RcuGpu7</recordid><startdate>199501</startdate><enddate>199501</enddate><creator>White, Harvey D</creator><creator>French, John K</creator><creator>Hamer, Andrew W</creator><creator>Brown, Michael A</creator><creator>Williams, Barbara F</creator><creator>Ormiston, John A</creator><creator>Cross, David B</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199501</creationdate><title>Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy</title><author>White, Harvey D ; French, John K ; Hamer, Andrew W ; Brown, Michael A ; Williams, Barbara F ; Ormiston, John A ; Cross, David B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-450543117941942cefbcdf1f85424a8dfad1cf555e99e319b150f861aae4d2c43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Aspirin - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Coronary Angiography</topic><topic>Coronary Disease - complications</topic><topic>Coronary Disease - epidemiology</topic><topic>Coronary Disease - prevention & control</topic><topic>Coronary Vessels - drug effects</topic><topic>Dipyridamole - administration & dosage</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prognosis</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Thrombolytic Therapy</topic><topic>Time Factors</topic><topic>Vascular Patency - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>White, Harvey D</creatorcontrib><creatorcontrib>French, John K</creatorcontrib><creatorcontrib>Hamer, Andrew W</creatorcontrib><creatorcontrib>Brown, Michael A</creatorcontrib><creatorcontrib>Williams, Barbara F</creatorcontrib><creatorcontrib>Ormiston, John A</creatorcontrib><creatorcontrib>Cross, David B</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>White, Harvey D</au><au>French, John K</au><au>Hamer, Andrew W</au><au>Brown, Michael A</au><au>Williams, Barbara F</au><au>Ormiston, John A</au><au>Cross, David B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1995-01</date><risdate>1995</risdate><volume>25</volume><issue>1</issue><spage>218</spage><epage>223</epage><pages>218-223</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>Objectives. This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction.
Background. Patency of the infarct-related artery is an important determinant of prognosis after myocardial infarction. The incidence of late reocclusion and the effects of antiplatelet therapy are unknown.
Methods. To investigate the importance of antiplatelet therapy for the prevention of late reocclusion, 215 patients who had a patent infarct-related artery 4 weeks after myocardial infarction were randomized in a double-blind manner to receive either a combination of 25 mg of aspirin and 200 mg of dipyridamole twice daily or placebo. One hundred fifty-four patients underwent further coronary arteriography 1 year later.
Results. At 1 year, 38 (25%) of 154 patients had reocclusion of the infarct-related artery; 18 (23%) of 79 patients receiving aspirin and dipyridamole had late reocclusion versus 20 (27%) of 75 who received placebo (p = NS). The rate of reocclusion was related to the severity of the residual coronary artery stenosis at 4 weeks (<50% stenosis 9.2%; 50% to 69% stenosis 11.6%; 70% to 89% stenosis 30.4%; ≥ 90% stenosis 70%, p < 0.01). The majority of reocclusions were silent, and only 17 (45%) of 38 were clinically associated with further infarction. There were no differences for a hierarchic end point of cardiac death, myocardial infarction or revascularization (14.8% aspirin and dipyridamole vs. 17.8% placebo).
Conclusions. Late reocclusion of the patent infarct-related artery is a frequent event, occurring in 25% of patients. Antiplatelet therapy with the combination of aspirin and dipyridamole does not alter the overall rate of late reocclusion. Other strategies are required to reduce late reocclusion.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>7798505</pmid><doi>10.1016/0735-1097(94)00331-J</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 1995-01, Vol.25 (1), p.218-223 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77086849 |
| source | MEDLINE; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Aspirin - administration & dosage Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Coronary Angiography Coronary Disease - complications Coronary Disease - epidemiology Coronary Disease - prevention & control Coronary Vessels - drug effects Dipyridamole - administration & dosage Double-Blind Method Drug Therapy, Combination Female Follow-Up Studies Humans Male Medical sciences Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - etiology Myocardial Infarction - mortality Pharmacology. Drug treatments Platelet Aggregation Inhibitors - therapeutic use Prognosis Recurrence Risk Factors Thrombolytic Therapy Time Factors Vascular Patency - drug effects |
| title | Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: Effects of antiplatelet therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A34%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequent%20reocclusion%20of%20patent%20infarct-related%20arteries%20between%204%20weeks%20and%201%20year:%20Effects%20of%20antiplatelet%20therapy&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=White,%20Harvey%20D&rft.date=1995-01&rft.volume=25&rft.issue=1&rft.spage=218&rft.epage=223&rft.pages=218-223&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/0735-1097(94)00331-J&rft_dat=%3Cproquest_cross%3E77086849%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77086849&rft_id=info:pmid/7798505&rft_els_id=073510979400331J&rfr_iscdi=true |